Nocdurna (Desmopressin)

Desmopressin, the active ingredient in Nocdurna, is a vasopressin analog presented as a sublingual formulation for sublingual use. It is employed to manage central diabetes insipidus, nocturnal enuresis in children and adults, and certain bleeding disorders by enhancing water reabsorption and promoting hemostasis, and is approved for use in the European Union.

GNH USA supplies Nocdurna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics across multiple regions.

Desmopressin acts on the antidiuretic hormone pathway to control water balance and coagulation.

Central diabetes insipidus: reduces excessive urine output by increasing renal water reabsorption. Nocturnal enuresis: decreases nighttime bedwetting episodes by concentrating urine. Bleeding disorders (e.g., hemophilia A, von Willebrand disease): enhances clot formation by stimulating V1 receptors.

Desmopressin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate pain in the head. - Nausea: feeling of stomach upset. - Hyponatremia: low blood sodium causing fatigue or confusion. - Facial flushing: transient redness of the skin.

Serious or Rare Side Effects: - Severe hyponatremia with seizures: dangerously low sodium leading to neurological symptoms. - Thromboembolic events: blood clots such as deep vein thrombosis. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing desmopressin, clinicians should consider several safety precautions. - Assess fluid balance: monitor intake and output to avoid water overload. - Check serum sodium: baseline and periodic measurements to detect hyponatremia. - Avoid in uncontrolled hypertension: V1 activation may raise blood pressure. - Use caution in patients with renal impairment: reduced clearance may increase exposure. - Concomitant use with other antidiuretic agents: increase risk of hyponatremia. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Desmopressin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Concomitant use of carbamazepine or phenytoin: induces hepatic enzymes that reduce desmopressin levels. - Combined with other antidiuretic agents (e.g., chlorpropamide, thiazide diuretics): markedly increases risk of hyponatremia.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may potentiate antidiuretic effect and affect renal function. - Selective serotonin reuptake inhibitors: potential additive effect on water retention. - ACE inhibitors or ARBs: may enhance hyponatremia risk, requiring monitoring.